Abstract
Over the last decades, beta-blockers have been a key component of heart failure therapy. However, currently there is no method to identify patients who will benefit from beta-blocking therapy versus those who will be unresponsive or worsen. Furthermore, there is an unmet need to better understand molecular mechanisms through which heart failure therapies, such as beta-blockers, improve cardiac function, in order to design novel targeted therapies. Solving these issues is an important step towards personalized medicine. Here, we present a comprehensive transcriptomic analysis of molecular pathways that are affected by beta-blocking agents and a transcriptomic biomarker to predict therapy response.
Original language | English (US) |
---|---|
Pages (from-to) | 107-121 |
Number of pages | 15 |
Journal | JACC: Basic to Translational Science |
Volume | 1 |
Issue number | 3 |
DOIs | |
State | Published - Apr 1 2016 |
Keywords
- beta-blocking agents
- biomarker
- gene expression
- heart failure
- transcriptomics
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine